# A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases

> **NCT00554229** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 896 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** ZD4054
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00554229
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2010-07
- **Final completion:** 2011-08
- **Target enrollment:** 896 (ACTUAL)
- **Last updated:** 2016-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00554229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00554229, "A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00554229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*